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Any process in which competing solutions replicate with errors and numbers of their copies de-
pend on their respective fitnesses is the evolutionary optimization process. As during carcinogenesis
mutated genomes replicate according to their respective qualities, carcinogenesis obviously qualifies
as the evolutionary optimization process and conforms to common mathematical basis. The opti-
mization view accents statistical nature of carcinogenesis proposing that during it the crucial role
is actually played by the allocation of trials. Optimal allocation of trials requires reliable schemas’
fitnesses estimations which necessitate appropriate, fitness landscape dependent, statistics of pop-
ulation. In the spirit of the applied conceptual framework, features which are known to decrease
efficiency of any evolutionary optimization procedure (or inhibit it completely) are anticipated as
”therapies” and reviewed. Strict adherence to the evolutionary optimization framework leads us to
some counterintuitive implications which are, however, in agreement with recent experimental find-
ings, such as sometimes observed more aggressive and malignant growth of therapy surviving cancer
cells.
INTRODUCTION
The term cancer refers to hundreds types of neo-
plasms which share specific prototypical traits, sum-
marized by Hanahan and Weinberg [1], collectively
leading to malignant growth. During the past few
decades molecular biologists have produced much
cancer-related data which has shown cancer as an
extremely stochastic, heterogeneous and complex
disease [2]. To analyze them, cancer research ap-
plies many concepts originally developed in different
branches of science, such as applied mathematics,
nonlinear dynamical systems, and statistical physics.
At present, evolutionary nature of carcinogenesis is
accepted and implications for cancer robustness (ex-
emplified by resistance to therapy) are often empha-
sized [3, 4]. Darwinian view to carcinogenesis im-
plicitly puts genetic (and epigenetic) changes into
microenvironmental context [5]. Consequently, tu-
mor microenvironment is viewed as an eventual tar-
get for chemoprevention and cancer reversion [6, 7].
On the other hand, anticancer research and therapy
concentrate mainly on molecular data and tend to
overlook its evolutionary nature.
Optimality model applied in experimental evolu-
tion [8] describes the evolution as simple generalized
trade-offs, presuming that genomes adapt success-
fully and freely enough and, consequently, genetic
details become irrelevant. Mathematical approaches
to carcinogenesis often apply concepts of feedback
and optimal control theory [9] instead of molecular
or genetic data. Komarova et al. [10] have solved
the optimization problem for cancerous growth and
proposed optimal strategies. However, as they state,
the ideal (optimal) strategy may be not realistic due
to many constraints in nature which escape model-
ing, but can make a strategy impossible.
In the paper we concentrate on the abstract mech-
anisms of attaining an optimal strategy instead of
the strategy itself. We view any process in which so-
lutions replicate with errors and numbers of their
copies depend on their respective qualities as an
evolutionary optimization process. As carcinogen-
esis conforms the above definition, we identify it
with an evolutionary optimization process and ap-
ply concepts and results of the long lasting research
in the evolutionary optimization [11]. Keeping in
mind an eventual therapeutic application, we focus
on those aspects of evolutionary optimization which
decrease or inhibit efficiency of the optimization pro-
cess. Strict adherence to the optimization frame-
work has led us to counterintuitive implications.
EVOLUTIONARY OPTIMIZATION
In the optimization theory, the quality of a solu-
tion is usually defined explicitly in the form of a
fitness function (also fitness landscape or fitness),
quantifying how well a candidate solution meets re-
quired criteria. The ultimate aim of the optimiza-
tion procedure is to find a solution for which the fit-
ness function receives optimum value. Large group
of optimization algorithms, called evolutionary algo-
rithms (EA), performs the task by mimicking biolog-
ical evolution implementing the genetic-like mecha-
nisms, such as mutation, selection and reproduction.
Applying EA in various engineering optimization ap-
plications has enabled to recognize those aspects of
fitness landscapes which support efficient evolution-
ary optimization and, at the same time, those which
prevent it. Theoretical analysis of the most popular
2EA variant, the genetic algorithms (GA), has been
performed by J. H. Holland [11]. In the simplest en-
gineering applications, canonical GA (CGA) applies:
1. initial population of random binary strings is gen-
erated
1011101011 ...
0001100101 ...
.
1011110010 ...
2. each of the bit string is projected and scaled to
get the real parameter set r = (r1, r2, · · ·)
1001· · ·1010︸ ︷︷ ︸
r1
0110· · ·0111︸ ︷︷ ︸
r2
· · ·
and its fitness function value φ(r) is determined
3. child population of the bit strings is constructed
from the parents population applying the genetic op-
erators - selection depending on the strings fitnesses,
crossover and mutation; after it is complete it re-
places the parent population
4. until some convergence criterion applies go to the
step 2.
Theoretical analysis of the process enabled to iden-
tify the driving force behind the biological-like ma-
nipulations with binary strings representing param-
eters of the model. It was recognized that the
population-based optimization algorithm is driven
by the fitnesses of the correlations of bits in the bi-
nary strings (called ”schemas”). The schema can
be viewed as a bit pattern over the bit positions in
the string. If the bit alphabet {0,1} is assumed, the
schema can be easily constructed over the ternary
alphabet {0,1,*}, where ’*’ matches both, 0 and 1,
at the respective position:
Let’s have 4 binary strings
A 10100101
B 01011011
C 11100010
D 00010001
and two schemas, X and Y
X *1***01*
Y 0*01***1
The schema X is contained in the strings B and C,
the schema Y in the strings B and D. It is usually
said that strings B and C are instances of the schema
X and the strings B and D are the instances of the
schema Y.
Specificity and robustness of the schemas are quanti-
fied by the schema order, O, and defining length, δ.
The schema order is the number of fixed positions in
the schema. The defining length is the distance be-
tween the leftmost and the rightmost fixed positions.
To predict the number of instances of a schema in
generation t+1, Holland derived the schema theorem
(ST) [11]
N t+1 ≥ N t
Φt
φt
[
1− Pc
δ
l − 1
−OPm
]
, (1)
where N t and N t+1 are numbers of instances of the
schema in t and t+1, respectively, Pc is the probabil-
ity of strings crossover, Pm is mutation rate, l is the
length of the binary string, φt is the average fitness
in the population, and Φt is the schema fitness in t
defined as the average fitness of all the instances of
the schema in the population in t. ST (1) states
that during the GA optimization the number of
the above average schemas increases on the account
of less favorable schemas. Moreover, it has been
demonstrated, that GA allocates its trials among al-
ternative solutions during the search (known as k-
arm bandit problem) in optimum way as long as the
schemas’ fitnesses are correctly estimated [11].
As in the paper we have identified carcinogene-
sis with the evolutionary optimization process, any
feature or mechanism which decreases efficiency of
the optimization process is interesting from the
point of view of its eventual therapeutic applica-
tion. Recognizing ST (1) as the principal mecha-
nism driving the evolutionary optimization, an ex-
plicitly optimization-preventing therapy can be iden-
tified with substituting into (1) wrong schemas’ fit-
nesses estimates. Below we list in the GA literature
most often presented reasons preventing reliable es-
timates of the schemas’ fitnesses.
i) Too large sampling errors. The factors influencing
the reliability of statistical sampling are the number
of evaluated candidate solutions and their distribu-
tion in the search space (i.e. population heterogene-
ity). They should cover as much of the search space
(fitness landscape) as possible so that the conver-
gence to the optimum was as probable as possible.
The sampling errors can be reduced by the appro-
priate choice of mutation rate. If mutation rate is
too low, optimization sticks in a suboptimal solu-
tion (known as premature convergence). If mutation
rate is too high, optimization procedure turns into
so-called blind search.
ii) Dynamic fitness landscape. As the evolutionary
optimization procedure converges towards optimum
solution in a stationary fitness landscape, hetero-
geneity of the population decreases. The parts of
the search space near the optimum become over-
populated, and, at the same time, other parts only
3sporadically populated, or even empty. The role of
the observed increase of population heterogeneity in
changed environment is well interpretable using the
terms of evolutionary optimization, namely evolu-
tion algorithms in dynamic environments. There-
fore, mechanisms of heterogeneity maintenance have
been developed in optimization theory and deeply
studied [12]. Efficient transition from the old opti-
mum to optimum(a) in a new fitness landscape re-
quires i) detection of the fitness landscape change,
and ii) response to that change [12]. For that, can-
didate solutions must be appropriately distributed
in the search space so that evolutionary algorithms
could perform representative statistical sampling to
determine reliable schemas’ fitnesses estimates which
are necessary for optimal allocation of trials during
optimization. If there are no (or too few) evalua-
tions in the changed part of the fitness landscape,
the change goes undetected.
iii) Deceptiveness of fitness landscape. To answer
the question which fitness landscapes are GA-hard,
Bethke [13] expressed a fitness function as a linear
combination of Walsh monomials and showed the re-
lationship between the schema’s fitness and Walsh
coefficients. Consequently, he applied the Walsh
transform to characterize functions as easy or hard
for GA optimization. It has been understood that
the principal problem for GA optimization is the
class of deceptive fitness functions, in which lower or-
der (lower number of defined bits) schemas lead the
search towards bad higher order schemas. Goldberg
showed the possibility of constructing high-order de-
ceptive functions using low-order Walsh coefficients
in special cases [14].
CARCINOGENESIS AS EVOLUTIONARY
OPTIMIZATION PROCESS
Exact convergence analysis of EA requires much bet-
ter mathematical definition of the relevant fitness
landscape and more obvious parametrization of a
solution than one typically disposes with biological
systems. Regarding the above introduced schema
formalism a few differences between CGA and car-
cinogenesis should be mentioned. At first, carcino-
genesis is an asexual process, therefore constant Pc
in (1) equals zero. The second difference is that no
spatial relation between offsprings and their parents
is assumed in (1). The third difference regards un-
known parametrization - obviously higher structures
than nucleotides (or genes) are relevant. Neverthe-
less, neither of the differences puts in doubt impor-
tance of reliable estimates of the schemas’ fitnesses
for optimal allocation of trials during carcinogenesis.
In addition, as often used in evolutionary optimiza-
tion practice, we use the term optimum solution in
a sense of a winning solution, i. e. the best solution
obtained after reasonable (or affordable) long opti-
mization, instead of exact, mathematically proved,
solution.
Fitness landscape
The term represents central concept in biological
evolution as well as in optimization theory [15]. In
biology, the fitness is usually understood in a sense
of ”reproduction” fitness, meaning that the more
copies solution has the more fit it is (and vice versa),
and obtains factual meaning in specific environment
and time scales. During the genome’s evolution se-
lection acts at two different hierarchical levels re-
spective to the two units of replication: cells and
organisms (multicellular bodies). As a result, the
genome is the trade-off between two processes: i)
maximization of the multicellular (organismic) re-
production fitness (acting during millenia), and ii)
maximization of cellular reproduction fitness (act-
ing during individual lifespan), respectively. The
former process presumes social cooperation of cells
(such as limited replicative potential, production of
growth signals, sensitivity to antigrowth signals, cel-
lular senescence, apoptosis, etc.) and severe prohi-
bition of the cells’ selfishness, the latter favors self-
ishness instead of cooperation [16]. The trade-off
is mediated by the initial genomic stability, evolved
to postpone short scale evolution in the respective
environment beyond reproduction period of the re-
spective organism.
Heterogeneity
Extensive genomic studies by Sjo¨blom et al. [2] have
clearly demonstrated extreme heterogeneity in col-
orectal cancer tumors. They have revealed that mu-
tational patterns in samples of colorectal cancers are
unexpectedly individualistic, with none of the three
most often mutated genes (APC, p53, K-ras) mu-
tated in all the samples [17]. It has been shown
that sets of mutated genes in two samples of col-
orectal cancers overlap to only a small extent and it
is anticipated to be general feature of most solid tu-
mors [18]. Similarly, resuming studies in breast and
renal cancer, Gatenby and Frieden [19] concluded
that probably no prototypical cancer genotype ex-
ists and every tumor seems to possess a unique set
of mutations indicating that multiple genetic path-
ways may lead to invasive cancer as would be ex-
pected in a stochastic non-linear dynamical system.
Clonal diversity in a subset of patients with early
stage haematopoietic malignancy has been demon-
strated and it has been shown that such clones may
arise independently [20]. It has been also observed
[21], that time to disease progression and overall
survival after treatment were significantly shorter in
those patients with EGFR heterogeneity. Maley et
4al. [22] have demonstrated that clonal diversity pre-
dicts progression to cancer and that accumulation
of viable clonal genetic variants is a greater risk for
progressing to cancer than homogenizing clonal ex-
pansion. Mathematical model by Komarova et al.
[10] shows that tumors thrive when cancerous cells
mutate to speed up malignant transformation, and
then stay that way by turning off the mutation rate.
Interpretation of heterogeneity is crucial for under-
standing of carcinogenesis. It can be, in extreme
cases, interpreted either as noise hiding a common
pattern, or redundancy (all the cases are causative as
a whole, no common pattern exists). If interpreted
as a noise, the effort to filter it out by analyzing as
many cancer cases as possible to see the common
mechanism is justified. If, however, each sample is
interpreted as a unique, nevertheless causative set of
genes, alternative approaches are needed. The above
mentioned studies at genetic level [2, 17, 18, 23] indi-
cate that heterogeneity should be interpreted in the
latter way. They report that every tumor harbors
a complex combinations of low-frequency mutations
thought to drive the cancer phenotypes [24]. Con-
sequently, a strategy to study mechanisms of cancer
by reducing heterogeneity may be assumed to be a
flawed approach [25].
Optimization behind
Putting fitness landscape and heterogeneity into op-
timization context, the wild-type genome represents
optimum solution in the respective past fitness land-
scape; its further optimization in unchanged fitness
landscape is, by definition, inhibited. After the
fitness landscape has changed, optimization of the
genome becomes possible. Regarding the structure
of the fitness landscape, during the optimization two
fitness landscapes are sampled, each for the respec-
tive unit of replication - organism or cell. As there
are many cellular fitness evaluations during the or-
ganism’s lifetime, only cellular fitness landscape may
be sampled representatively enough to provide reli-
able schemas’ fitnesses (1) which result in optimal
allocation of trials driving the short time evolution
of the genome into an optimum in the changed cel-
lular fitness landscape. The organismic fitness land-
scape, selecting for intercellular cooperation, does
not apply during the lifetime of the body and the
optimization process is driven purely by cellular fit-
ness landscape for which the intercellular coopera-
tion is not selectable trait. From this point of view,
any short-scale change of the fitness landscape is not
only mutagenic but also carcinogenic, as it selects
for destroying intercellular cooperation. Applying
the quasispecies model [26], Forster and Wilke have
demonstrated that competitive dynamics of finite
populations of as few as two strains, adapted to the
long-term and short-term environment changes, re-
spectively, is quite complex [27].
Heterogeneity represents crucial aspect of carcino-
genesis [25]. At the same time, in engineering
applications, evolutionary optimization starts with
heterogeneous, typically randomly generated, ini-
tial population of candidate solutions. In the case
of stationary fitness landscapes, heterogeneity de-
creases towards some minimum level as the optimiza-
tion procedure converges to the best solution (the
analogy with a homogenizing clonal expansion in-
flicts itself), despite keeping constant mutation rate.
On the other hand, evolutionary optimization in
changing fitness landscapes [12] shows importance
of avoiding total homogenization. In computer ex-
periments where mutation rate is not exempted from
optimization, its increase (followed by the increase of
heterogeneity) is observed after the fitness landscape
has changed. It has been reliably demonstrated that
rapid or extreme environmental change leads to the
selection for greater evolvability [28]. Similarly, se-
lection of mechanisms for increased mutation rate
in biological systems, like RNA viruses, in unstable
environments was reported [29]. Donaldson-Matasci
et al. [30] have shown that optimal amount of di-
versity depends on environmental uncertainty which
can lead to the evolution of either generalist or spe-
cialist strategy.
Cancer-susceptibility genes are classified as caretak-
ers, gatekeepers and landscapers. Mutations in care-
takers leads to genomic instability, mutated gate-
keepers are responsible for increased cellular prolif-
eration and landscapers defects generate an abnor-
mal stromal environment. In general, the cancer-
susceptible genes govern statistics of the cell popu-
lation, either directly (caretakers and gatekeepers),
or indirectly by maintaining fitness landscape (land-
scapers). Within the frame of evolutionary theory it
is understood that heterogeneity confers cancer cells
population with the ability to cope with environment
uncertainties. Optimization theory derives efficiency
of an optimization method from its ability to allocate
appropriately future trials. The schema theorem (1)
guarantees giving at least exponentially increasing
number of trials to the observed best building blocks
[31]. Implicitly, optimal allocation of trials between
alternative solutions requires as reliable schemas’ fit-
nesses estimates as possible. In addition, as evolving
clones implicitly undergo competition, the schemas’
fitnesses must be determined as fast as possible. For
that, representative (regarding the respective fitness
landscape) statistics of the population must be at
hand. The ability of the clone to evolve (or not)
towards representative statistics comes from specific
defects in cancer susceptibility genes.
Causality in evolutionary processes is actually pro-
vided by the feedback from environment. The evo-
lutionary process is a fitting procedure, which is
the method of solving (typically ill-posed) inverse
problems [32]. Enormous genetic heterogeneity of
5cancers indicates that most cancer occurrences are
the unique solution of the fitting problem. It im-
plies that the fitting problem solved by cancer is
highly underdetermined, which results in the arbi-
trariness of a fit (i. e. model) and it is consistent
with the metaphoric conclusion by Witz and Levy-
Nissenbaum [5], who stated ”...the extreme com-
plexity of the signaling cascades operating in the
microenvironment and the interactive cross-talk be-
tween these cascades, generates the feeling that ’any-
thing that can happen - it will”.
IMPLICATIONS FOR THERAPY
Traditional therapies are based on comparisons of
cancerous and non-cancerous cells, which, by def-
inition, presumes existence of reliable enough (in
an ideal case dichotomic) splitting into two respec-
tive groups. Consequently, therapeutic actions are
taken to attack the tumor cells group (cancer cell-kill
paradigm). It is implicitly believed that therapeutic
efficiency depends on how close to dichotomic the
splitting is. For instance, the two main therapeutic
treatments, chemotherapy and radiation, exploit the
enhanced sensitivity of cancer cells to DNA damage.
Novel targeted and gene therapies go even further
- they are aimed to interfere directly with the spe-
cific molecules or genes participating in carcinogen-
esis (the ’magic bullet’ concept). The effort to find
the criterion(a) enabling to approach to dichotomic
splitting as close as possible is omnipresent in can-
cer therapy. Varshavsky [33] proposed the therapy
which distinguishes cancer and normal cells accord-
ing to harboring (or not) homozygous DNA dele-
tions. Skordalakes [34] points out that inappropri-
ate activation of a single enzyme, telomerase, is as-
sociated with the uncontrollable proliferation of cells
observed in as many as 90% of all of human cancers
and proposes that the high-resolution structure of
the enzyme will be the key to efficient anti-cancer
therapies.
However, putative existence of dichotomic splitting
is in contradiction with the evolutionary nature of
carcinogenesis which, as any other evolutionary pro-
cess, crucially depends on the variability of traits
observed at many levels [2, 17, 35, 36]. Extreme tu-
mor cells heterogeneity gives cancer robustness, ex-
emplified by the resistance to therapy [3, 4], and it is
the most tormenting problem in cancer research to
which therapies and experimental models must face
[37, 38]. Heng et al. [25] emphasize the key role of
heterogeneity by stating that without heterogeneity,
there would be no cancer.
Below we present specific insights and implications
for anti-cancer therapy stemming from the above
presented optimization view to carcinogenesis. Some
of them are intuitive and consistent with established
anti-cancer therapies, some others are quite coun-
terintuitive and, hopefully, novel and put in ques-
tion some current trends in the development of anti-
cancer therapies. Within the frame of the above
outlined identification of carcinogenesis as the evolu-
tionary optimization process, therapy is a purpose-
ful effort to decrease the efficiency of that optimiza-
tion process or, hopefully, inhibit it completely. For
that purposes, we have listed above the three most
frequent obstacles to the efficient evolutionary op-
timization, stemming from validity of the schema
theorem (1). These are: too large sampling errors,
dynamic (or changing) fitness landscapes and decep-
tiveness of fitness landscape. In all the cases the es-
timation of the schemas’ fitnesses is not reliable (or
systematically wrong) which prevents the optimiza-
tion process to allocate its trials optimally.
i) Too large sampling errors. It is understood that
heterogeneity plays a central role in evolution and
provides species (or clones) with the capacity to cope
with environmental uncertainty. On the other hand,
if it exceeds a certain threshold, deleterious effects
outweigh the above selection advantage. The exis-
tence of the critical mutation rate in evolution be-
yond which Darwinian selection does not operate has
been predicted by Eigen’s theory of quasispecies [26].
Sole and Deisboeck [39] applied the simple mathe-
matical model of quasispecies dynamics to quantify
the upper limit of affordable genetic instability (error
threshold) in cancer cells population, beyond which
genetic information is lost. Consistently with the
fact that tumor cells have defective stability path-
ways, Cahill et al. proposed that tumor cells could
be target for direct attack by instability drugs [40].
However, from the point of view of the evolution-
ary optimization theory, competitiveness of the clone
depends on its capability to allocate its further tri-
als among emerging alternatives [11] which requires
representative statistics of the cells population, not
merely specific genetic (in)stability. Therefore we
speculate that forced increase of sampling errors by
instability drugs, abruptly shifting population statis-
tics away from the optimal in the respective fitness
landscape, would be compensated by selecting for
change(s) in other evolutionary attribute(s), such as
reproduction rate, cellular mortality rate, internal
stability (the mechanism does not matter at this
point), etc.
ii) Dynamic fitness landscape. Changing the fitness
landscape can be a double edged sword. On the
one hand, cancer cells reveal increased adaptivity
enabling them to respond to environmental changes
to keep high (reproductive) fitness. On the other
hand, higher adaptivity of cancer cells can be thera-
peutically exploited, as outlined by Maley et al. [41].
6They proposed to select for the cells sensitive to cy-
totoxins before applying cytotoxic therapy.
iii) Deceptiveness of fitness landscape. Deceptive
landscapes can be interpreted as the landscapes in
which correlations of traits systematically lead away
the search from the global optima. To our knowl-
edge, there is no therapeutic approach explicitly ex-
ploiting deceptiveness of the fitness landscape. We
anticipate that combining biological intuition, the
results of mathematical analysis of deceptive fitness
landscapes [14] and digitized evolution [42] can bring
novel insights into the evolution of cancer phenotype.
Is therapy a penalty function?
From the evolutionary optimization point of view
therapy is a purposeful change of the fitness land-
scape, namely decrease of reproduction fitness in
the relevant area of the search (sequence) space
at reasonable time scales. All the well estab-
lished traditional therapies (surgery, radiotherapy
and chemotherapy) make an effort to remove all the
cancer cells, or, at least, as many of them as possible.
Evolutionary optimization theory implies that ulti-
mate therapeutic success depends not only on how
many cancer cells survived the therapy, but also on
the distribution of the cells in the search space, i. e.
statistics of the remaining population. If the pop-
ulation statistics is sufficient for the efficient opti-
mization, the regrowth appears. Below we present
eventual counterintuitive consequence of therapy re-
sulting from the optimization facet of carcinogenesis.
It has been reported that therapy-surviving tumor
cells are frequently more malignant and aggressive
than the initial tumor population [43]. Inhibition of
angiogenesis has been envisioned as promising an-
ticancer therapeutic strategy for a long time [44].
Since then, modes of resistance to antiangiogenic
therapy, such as evasive and intrinsic resistance, has
been reported [45]. It has been found by Paez-Ribes
at al. [46] that targeting the vascular endothelial
growth factor (VEGF) induces (apart from anti-
tumor effects to primary tumor) higher invasiveness
and, in some cases, increased lymphatic and dis-
tant metastasis. Ebos et al. [47] have found that
the VEGFR/PDGFR kinase inhibitor can acceler-
ate metastatic tumor growth and decrease overall
survival in mice receiving short-term therapy. Simi-
larly, it has been reported that the resistance to some
synergistic drug combinations evolves faster than the
resistance to individual drugs [48]. In their review
Kim and Tannock [49] report that repopulation of
cancer cells after radiotherapy as well as chemother-
apy is often accelerated in comparison to untreated
cases. The mechanism of this acceleration has not
yet been understood.
In the spirit of our work we attribute the above in-
crease of invasiveness and acceleration of the evolu-
FIG. 1: 2-dimensional fitness landscape with one ”hill”
(crossed) prohibited by a penalty function. Dots show
sampled points. Without penalty, both hills would be
sampled.
tion of resistance during repopulation to the opti-
mization facet of carcinogenesis. In engineering ap-
plications of evolutionary optimization one often ap-
plies ad hoc penalty function to disadvantage some
part(s) of fitness landscape to accelerate convergence
of the process into the optimum in desirable parts
(Figure 1). The simplification of fitness landscape
enables to perform more representative schema sam-
pling of more promising parts at the same price ob-
taining more reliable schemas’ fitnesses evaluations
resulting, accordingly to (1), in closer-to-optimum
allocation of the trials among alternative solutions.
If cancer, metaphorically said, solves the optimiza-
tion problem, the same mechanism applies. We hy-
pothesize, that if therapy does not remove decisive
portion of cancer cells (hopefully all), it may, even-
tually, result in unwanted simplification of fitness
landscape for therapy-resistant clone(s). We empha-
size, that this hypothesis is aimed purely to interpret
sometimes reported cases when accelerated progres-
sion of therapy-resistant tumors was observed and it
does not propose any alternative to well established
therapies.
DISCUSSION
Recent experimental evidence shows that hetero-
geneity, stochasticity and dynamics play in carcino-
genesis much more important role than envisioned
a few decades ago. This new picture requires cor-
responding conceptual framework. Here presented
evolutionary optimization view to carcinogenesis im-
plicitly includes connection between statistics of
cells population and statistics of fitness landscape
[27, 50, 51, 52, 53, 54] and applies results of long-
standing research in the stochastic evolutionary op-
timization algorithms, especially in dynamic fitness
7landscapes [12, 55]. Here we have put some of the
observed cancer features, such as increased hetero-
geneity, clonal expansion, consequences of changing
the fitness landscape and accelerated evolution of re-
sistance to chemotherapy into optimization scenario.
Carcinogenesis is, unquestionably, a physical pro-
cess. At the same time, it can be formally viewed,
as all the evolutionary processes, as the optimiza-
tion procedure. Straightforward approaches study
carcinogenesis and develop anticancer strategies an-
alyzing biochemical or genetic details. In the pa-
per we have speculated that it may be not relevant
per se. Instead, we have proposed that cancer re-
lates primarily to the cells population statistics and
all the therapies lead (more or less intentionally or
explicitly) to its modification. Traditional thera-
pies rely on comparison between cancerous and non-
cancerous cells which may be motivated by the long
lasting effort to reduce cancer cells population by
some straightforward action. Evolutionary view sug-
gests that carcinogenesis could be inhibited by a pur-
poseful modification of evolutionary attributes, such
as mutation rate, effective population size or gen-
eration time of the self-renewing cells [56]. Never-
theless, except for trivial cases, evolutionary theory
does not give instructive enough answer how should
be the evolutionary attributes changed. Here pre-
sented optimization view to carcinogenesis proposes
that the crucial mechanism of cancer progression is,
as in any other evolutionary optimization process,
optimal (or, more realistically, better than by other
clones) allocation of trials, based on more represen-
tative population statistics enabling more reliable es-
timations of schemas’ fitnesses (1). Efficiency of the
schema sampling depends on the number of sampled
points and their distribution in the fitness landscape,
as well as the cell’s fitness estimation time. These
attributes adapt to statistical features of the fitness
landscape by selecting respective mutations in genes
(a posteriori denoted as cancer-susceptible genes).
As, at the same time, efficiency of the sampling de-
termines the cancer’s perspective, we conclude that
the therapeutic outcome could be influenced by ma-
nipulation with statistical properties of the fitness
landscape, such as roughness or dynamics, in a pur-
poseful cancer-inhibiting way. The above statisti-
cal view may be relevant especially for advanced
malignancies, where high heterogeneity of the can-
cer cells population enables them to adapt success-
fully to therapeutically-changed environment. Clas-
sifying carcinogenesis as the evolutionary optimiza-
tion process does not contradict to often presented
view of cancer as the result of accumulating spe-
cific mutations in the only transformed cell. It em-
phasizes, however, importance to combine molecu-
lar data with statistical view which may play crucial
role before and during carcinogenesis. The princi-
pal question remains if the novel conceptual frame-
work can be exploited to trigger novel, explicitly
anti-optimization based, therapeutic approach.
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